Results 281 to 290 of about 362,523 (334)

Prevalence of <i>EGFR</i> mutations in patients with resected stage I-III non-small cell lung cancer: results from EARLY-EGFR Latin America study. [PDF]

J Thorac Dis
Kajatt EA, Perroud HA, Garcia-Herreros L, Suárez F, Puello Guerrero A, Tejado Gallegos LF, Donner N, Huggenberger R, Corrales L.   +8 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Mechanism of Non-Small Cell Lung Cancer-Derived Extracellular Vesicle miRNA hsa-let-7b-5p Targeting AP1S1 to Regulate M2 Macrophage Polarization. [PDF]

Int J Genomics
Liu L, Kou Z, Wang T, Shang Q, Zhang Q, Liu G, Ai J, Zhao Y, Sun C.   +8 more
europepmc   +1 more source

Discovery ofa Novel and Potent MET Transcription Inhibitor TargetingPromoter G‑Quadruplex forthe Treatment of NSCLC

Wenjian Min (11560191), Chunling Chen (79232), Zhongrui Shi (21085149), Huanaoyu Yang (14093611), Yanyin Wang (13047953), Junfeng He (4252039), Qiman Zhang (19830156), Yunchu Zhao (21466631), Yi Hou (148620), Jiayu Ding (12005975), Yasheng Zhu (8049617), Chengliang Sun (715954), Kai Yuan (289810), Peng Yang (296696), Xiao Wang (19312)   +14 more
openalex   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

The role of EGFR mutations in sensitivity of PD-1/PD-L1 blockade in non-small cell lung cancer. [PDF]

Am J Cancer Res
Guo J, Yang L, Li X, Rao X, Chen F, Wu P, Bi M, Yuan Z, Yang J, Wang S, Xia Z, Wang J, Liu S, Lv Q.   +13 more
europepmc   +1 more source

A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)

AstraZeneca
openalex   +1 more source

Atezolizumab + Chemotherapy for Advanced Non‐Small Cell Lung Cancer in Japanese Clinical Practice (J‐TAIL‐2)

Cancer Science, EarlyView.
The J‐TAIL‐2 prospective, observational study evaluated atezolizumab combined with several chemotherapy regimens in patients with advanced/metastatic non‐small cell lung cancer in routine clinical practice in Japan. The real‐world efficacy and safety of each atezolizumab combination were found to be comparable to those seen in the relevant global ...
Hiroshige Yoshioka, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Junichi Shimizu, Eisaku Miyauchi, Ichiro Yoshino, Toshihiro Misumi, Yasutaka Watanabe, Akito Hata, Akira Kisohara, Shoichi Kuyama, Masafumi Yamaguchi, Asako Miwa, Shunichiro Iwasawa, Misa Tanaka, Akihiko Gemma   +19 more
wiley   +1 more source

Computed tomography-based texture analysis for predicting adjuvant therapy response in postoperative patients with <i>EGFR</i>-mutant non-small cell lung cancer. [PDF]

J Thorac Dis
Wang D, Wang M, Song J, Yu Y, Cao T, Chen R, Zhang Z, Song D, Yang F.   +8 more
europepmc   +1 more source

A Transcriptomic Analysis of Cancer‐Stromal Interactome in Lung Cancer Xenograft Models

Cancer Science, EarlyView.
We conducted a comprehensive analysis of the lung cancer interactome to identify key ligand–receptor pairs involved in the aggressiveness of lung adenocarcinoma. Tumor necrosis factor superfamily member 12 and its receptor tumor necrosis factor receptor superfamily member 12A signaling axis may be potential candidates for therapeutic intervention for ...
Yuriko Takayama‐Isagawa, Daisuke Komura, Takayuki Isagawa, Yusuke Amano, Atsushi Kihara, Tamaki Miura, Taichiro Yoshimoto, Hiroyoshi Tsubochi, Kazutaka Fujita, Koichi Hagiwara, Makoto Maemondo, Tetsuo Ushiku, Shumpei Ishikawa, Noriyoshi Fukushima, Kentaro Inamura, Daisuke Matsubara, Toshiro Niki   +16 more
wiley   +1 more source